Company Overview
SCYNEXIS, Inc. operates as a biotechnology company dedicated to the drug development and treatment of difficult-to-treat and drug-resistant fungal infections within the United States market. The company specifically markets BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and aims to reduce the incidence of such conditions. This enterprise functions within the Healthcare sector, specifically categorized under the industry of Drug Manufacturers - Specialty & Generic, which implies a focus on niche therapeutic areas often requiring specialized research and development. The firm maintains a relatively small operational scale with a total market capitalization of $36.31M, annual revenue of $20.60M, and an employee count of 18. These valuation and revenue figures indicate that SCYNEXIS is a micro-cap entity with a modest market footprint, suggesting it is likely a pre-commercial or early-stage commercialization company rather than an established large-cap pharmaceutical player. The low employee count relative to the specialized nature of drug development further highlights the capital-intensive nature of the biotechnology industry where high-value assets are often generated by small teams.
Financial Health
The company reported total revenue of $20.60M over the trailing twelve months, yet it recorded a net income of $-8,609,000, revealing a significant negative gap that indicates substantial operating expenses or R&D costs that have not yet been offset by profitability. While the EBITDA metric is listed as N/A, the disparity between positive revenue and negative net income underscores a cost structure dominated by non-cash charges or high burn rates typical of biotechnology firms in the development phase. Despite the negative net income, the company generated positive free cash flow of $599,625, which provides a critical buffer for financial flexibility and suggests that capital expenditures are currently lower than operating cash generation. The gross margin stands at 100.0%, indicating that the cost of goods sold is effectively zero, likely due to the nature of the product lifecycle or manufacturing arrangements, while the operating margin is a robust 56.4%. However, the profit margin is negative at -41.8%, confirming that operating expenses significantly exceed operating income before interest and taxes. On the liability side, the company holds $40.03M in cash against $2.17M in debt, resulting in a debt-to-equity ratio of 4.41, which presents a complex picture of high leverage relative to equity but ample liquidity to service obligations. The current ratio is an exceptionally high 7.04, indicating that the company possesses more than seven times the current assets necessary to cover its short-term liabilities, pointing to very strong short-term liquidity. Return on Equity is negative at -16.5% and Return on Assets is -13.4%, metrics that reveal that management has not yet achieved positive returns on the capital deployed, a common characteristic for biotech firms awaiting product approvals or commercial milestones.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A due to the lack of positive net income, whereas the forward P/E is negative at -2.46, a figure that mathematically reflects the expectation of continued negative earnings in the near term rather than a traditional valuation multiple. The price-to-book ratio is 0.72, which indicates that the market is valuing the company at less than one times its book value, suggesting a discount to the theoretical liquidation value of its assets. The price-to-sales ratio is 1.76, and the EV/EBITDA is N/A; these alternative metrics suggest that valuation is driven primarily by revenue potential rather than current profitability or earnings power, a common approach for assessing early-stage biotechnology assets. The stock trades within a 52-week range between a high of $1.31 and a low of $0.56, and without the current price explicitly provided in the facts, the position relative to this range cannot be calculated, but the range itself defines the volatility envelope for the share. The beta value is 1.32, which indicates that the stock price is expected to be 32% more volatile than the broader market, reflecting the higher risk premium associated with small-cap biotechnology equities.
Growth & Income
The company reported revenue growth of 1808.5% year-over-year, while earnings growth is listed as N/A due to the negative earnings figure, implying that while top-line sales have expanded dramatically, profitability has not yet materialized. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders, which means any excess cash is retained within the business to fund research and development or operational expansion. The combination of massive revenue growth and zero dividend payout illustrates a classic growth-at-all-costs profile where the primary objective is market penetration and product approval rather than income generation. The overall growth and income profile is defined by extreme revenue expansion coupled with negative earnings and no dividend distribution, characteristic of a capital-intensive biotechnology firm in the growth phase of its lifecycle.